期刊论文详细信息
JOURNAL OF THE NEUROLOGICAL SCIENCES 卷:345
A dose-response study of thymosin β4 for the treatment of acute stroke
Article
Morris, D. C.1  Cui, Y.2  Cheung, W. L.1  Lu, M.3  Zhang, L.2  Zhang, Z. G.2  Chopp, M.2,4 
[1] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA
[2] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA
[3] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI 48202 USA
[4] Oakland Univ, Dept Phys, Rochester, MI 48309 USA
关键词: Thymosin;    Rat model;    Embolic stroke;    Neurorestorative therapy;    Actin-binding protein;    Oligodendrocyte;   
DOI  :  10.1016/j.jns.2014.07.006
来源: Elsevier
PDF
【 摘 要 】

Background: Thymosin beta 4 (T beta 4) is a 5 K actin binding peptide. T beta 4 improves neurological outcome in a rat model of embolic stroke and research is now focused on optimizing its dose for clinical trials. The purpose of this study was to perform a dose-response study of T beta 4 to determine the optimal dose of neurological improvement in a rat model of embolic stroke. Methods: Male Wistar rats were subjected to embolic middle cerebral artery occlusion (MCAo). Rats were divided into 4 groups of 10 animals/group: control, 2,12 and 18 mg/kg. T beta 4 was administered intraperitoneally 24 h after MCAo and then every 3 days for 4 additional doses in a randomized controlled fashion. Neurological tests were performed after MCAo and before treatment and up to 8 weeks after treatment. The rats were sacrificed 56 days after MCAo and lesion volumes measured. Generalized estimating equation was used to compare the treatment effect on long term functional recovery at day 56. A quartic regression model was used for an optimal dose determination. Results: T beta 4 significantly improved neurological outcome at dose of 2 and 12 mg/kg at day 14 and extended to day 56 (p-values <0.05). The higher dose of 18 mg/kg did not show significant improvement. The estimated optimal dose of 3.75 mg/kg would provide optimal neurological improvement. Conclusions: This study shown that T beta 4 significantly improved the long term neurological functional recovery at day 56 after MCAo with an optimal dose of 3.75 mg/kg. These results provide preclinical data for human clinical trials. (C) 2014 Elsevier B.V. All rights reserved.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jns_2014_07_006.pdf 971KB PDF download
  文献评价指标  
  下载次数:21次 浏览次数:0次